Questions List
***Posted onMarch 16, 2022 8:06 am
THanks. Virgilio Alberto Salinas Rodríguez from Peru (2011898 EBAH) appreciates allowing attendance at E-conference 3ed How to diagnose and treat acute leukemias. Posted onMarch 13, 2022 11:31 am
Thank you very much for this exciting meeting!
Jelena RoganovicPosted onMarch 13, 2022 11:30 am
In few months oral AZA will be available as mantainance in not transplanted patients. Could this change the indication to Tx in NPM1 pos patients?Posted onMarch 13, 2022 11:23 am
Kimmo :Did you observe MRD negative responses? Could you deliver Ven in the 400mg dosage or had you adapt the dosage
Gert OssenkoppelePosted onMarch 13, 2022 11:17 am
Kimmo :Did you observe MRD negative responses? Could you deliver Ven in the 400mg dosage or had you adapt the dosage
Gert OssenkoppelePosted onMarch 13, 2022 11:17 am
Thank you for a fantastic series of talks.. three questions/comments:
A) The UK NCRI Group is studying post-transplant maintenance CC486 in patients allografted for AML. Currently 230 patients recruited through the IMPACT trials network. Study closure anticipated Q3 2022
B) Could Anneke comment on timing of immunosuppression withdrawal in patients allografted for high risk AML/MDS noting that in the case study the patient was still on immunosuppression at 6 months post-transplant
C) Could Rafael specifically comment on indications for transplant in older patients (>60) with AML in CR1 noting the v high risk of relapse using chemo alone in this group and the fact that some predictors eg NPM1 may not apply in older patients
Thanks again! Charlie Craddock BirminghamPosted onMarch 13, 2022 11:16 am
what is the best treatment for steroid-refractory LIver GvHDPosted onMarch 13, 2022 11:16 am
how do you treat Sclerodema like (skin, fascia, muscle) chronic GvHD?Posted onMarch 13, 2022 11:14 am
How could The availability of oral AZA maintenance integrate the proposed flow chart decision about Allogeneic SCT in 1st CR in NPM1pos AMLPosted onMarch 13, 2022 11:10 am
Question for Prof Zeiser from Giorgia Battipaglia, Italy: in pts obtaining RP after ruxolitinib for SR-aGVHD, which drug(s) do you suggest? ThanksPosted onMarch 13, 2022 11:09 am
to Dr. Zeiser: you focused mainly on Ruxolitinib, how are these results compared to ECP for treatment of SR a- or c-GvHD?Posted onMarch 13, 2022 10:40 am
Why don,t stopp immediatly cyclosporin or fks Posted onMarch 13, 2022 9:53 am
Posted onMarch 13, 2022 9:42 am
Posted onMarch 13, 2022 9:42 am
What is the difference in toxicity (first induction cycle) between "intensive therapy" vs AZA-ven?Posted onMarch 13, 2022 9:42 am
Posted onMarch 13, 2022 9:08 am
The issue of oligoclonality in MLL rearranged patients is addressed in Europe by MLL breakpoint mapping and ASO assay design specific to the MLL rearrangement. This is needed for MRD monitoring and risk stratification in infant ALL. How is this managed in the USA?Posted onMarch 13, 2022 9:03 am
********* Day 4 *************Posted onMarch 13, 2022 8:56 am
Do you think that MRD assessment is clinically applicable in most patients >65y.o. for whom treatment options are more limited?Posted onMarch 13, 2022 8:28 am
Can clonoseq be used on DNA from FFPE material taken at diagnosis if the clinicians did not take a fresh sample for MRD target identification?Posted onMarch 13, 2022 8:26 am
A young patient with refractory relapse (post auto HSCT) Primary B cell lymphoma who achieved PR with Pembrolizumab based therapy went on to receive CART therapy. PET CT after one month of CART showed no reduction in the tumor. The CART cell were not detectable in the blood after infusion. What is the best option for this patient? A second CAR-T (?? at higher dose, ? combination with a PD-1 inhibitor. or sequential infusion of CAR-T ? He has no matched sibling donor.Posted onMarch 12, 2022 6:18 pm
to N Gökbuget : do you still consider chemotherapy for first relapse in Ph-neg ALL patient? If yes, in which cases?Posted onMarch 12, 2022 5:16 pm
Is blinatutmumab contraindicated in initial parkinson's disease?Posted onMarch 12, 2022 5:08 pm
we can not see the slides!Posted onMarch 12, 2022 4:58 pm
Thanks for correcting the clarity :)Posted onMarch 12, 2022 4:55 pm
resolved. Just want to mention that the screen appears blurred for this talk compared to previous. Posted onMarch 12, 2022 4:52 pm
the screen is still. No movement since Q3 posted. Posted onMarch 12, 2022 4:49 pm
Posted onMarch 12, 2022 4:45 pm
******* Session 5 **********Posted onMarch 12, 2022 4:38 pm
if a patient has severe cytopenia and BM hypoplasia (BM blast 2%) and oral GvHD, should the patients receive CART and if yes, should the dose of the lymphodepletion be reduced? are these factors going to reduce the efficacy of CAR-t? Posted onMarch 12, 2022 4:28 pm
CAR T cell is an alternative to locate unrelated HLA donorPosted onMarch 12, 2022 4:24 pm
CAR T cell 19/22 has benefit over CAR T cell 19 or CAR T cell 22Posted onMarch 12, 2022 4:22 pm
if there is no circulating CART at day 7 and day 14 after CART infusion, is there a role to repeat the infusion? Is there a role of sequential infusion (Day 0, Day 15 or day 21)? What can be done to improve the expansion and persistence? What is the level of PB CART that is acceptable to improve the clinical outcome?Posted onMarch 12, 2022 4:22 pm
Does prior CAR T-Cell therapy affect post-transplant complications? (M. Sevki Uyanik, Turkey)Posted onMarch 12, 2022 4:19 pm
Thanks for the nice presentations. Do you think that a null tumor burden (EMR negative) such as that achieved with immunotherapy such as inotuzumab, is a risk of post-CART relapse, and should be a risk to be taken into account when deciding on post-Cart ALLoTPH?Posted onMarch 12, 2022 4:16 pm
Beautiful music! :)Posted onMarch 12, 2022 3:39 pm
****** Debate 2 *********Posted onMarch 12, 2022 3:36 pm
ThanksPosted onMarch 12, 2022 3:32 pm
how do you select patient (no donor) that is suitable for autoHSCT?Posted onMarch 12, 2022 3:31 pm
Posted onMarch 12, 2022 3:29 pm
For post ALLO HSCT maintenance which TKI is the most appropriate?Posted onMarch 12, 2022 3:29 pm
maintenance Prednisone 200 mg for 4 days every 15 days, methotrexate 20 mg/m2 day 14 and imatinib 600 mg daily for 15 days. Maintain patient with ALL Ph positive with negative MRD.Posted onMarch 12, 2022 3:29 pm
KZF1 how do I diagnosePosted onMarch 12, 2022 3:22 pm
Ponatinib produce efecto cardiovascular que se ve en LMCPosted onMarch 12, 2022 3:21 pm
In the german guidelines BCR-ABL patients pos. patients are predicted high-risk and should recieve Allo SCT, after these results, would you still recommend that?Posted onMarch 12, 2022 3:19 pm
thank you very much! I would like to ask, for a Ph+ALL patient that underwent alloSCT would you continue a maintenance treatment with a TKI and when would be the best timing (due to drug interactions)?
Posted onMarch 12, 2022 3:16 pm
thank you very much! I would like to ask, for a Ph+ALL patient that underwent alloSCT would you continue a maintenance treatment with a TKI and when would be the best timing (due to drug interactions)?
Posted onMarch 12, 2022 3:16 pm
thank you very much! I would like to ask, for a Ph+ALL patient that underwent alloSCT would you continue a maintenance treatment with a TKI and when would be the best timing (due to drug interactions)?
Posted onMarch 12, 2022 3:16 pm
How frequently have you seen that bcr-abl is negative by PCR but NGS MRD is positive?
What is your approach to those patients?Posted onMarch 12, 2022 3:12 pm
What is the best method to monitor MRD: BCR-ABL PCR, IgTCR PCR or NGS?Posted onMarch 12, 2022 3:10 pm
For ALL Ph positive after finishing of both arms of Hyper-CVAD plus ponatinib, for maintenance, can we give for maintenance 6MP, MTX, ONCOVIN WITH PONATINIB FOR 16 months or 2 years? Posted onMarch 12, 2022 3:04 pm
To Sabina Chiaretti: Thank you for your excellent talk. What kind of MRD do you think is more reliable to decide to transplant patients with Ph+ ALL : BCR-ABL or IG/TR ?Posted onMarch 12, 2022 2:55 pm
**** Rounudtable 2 ***********Posted onMarch 12, 2022 2:19 pm
Do you think targeting leukemic stem cells+ B-cell antigen through CAR-T therapy may have better outcome and persistence of response? Dr Zafar Iqbal, Pakistan Posted onMarch 12, 2022 2:09 pm
Posted onMarch 12, 2022 2:09 pm
Looks like B cell aphasia is being used as a surrogate of persistent of CAR-T cells, is there real word data on persistence of CARs and long term outcomes?Posted onMarch 12, 2022 2:08 pm
If B-ALL relapse post ALLO- HSCT, patient achieved Flow- MRD negative after CART cell but the CART became undetectable, would you do a second AlloHCT? or give another CART?Posted onMarch 12, 2022 2:08 pm
For a patient with relapsed or refractory ALL to chemotherapy, you would prefer CART or blinatumomab prior alloSCTPosted onMarch 12, 2022 2:04 pm
Is there any data regarding outcome of CAR-T therapy after first negative MRD? Dr Zafar Iqbal, Pakistan. Posted onMarch 12, 2022 2:01 pm
if patient with post HSCT relapse B-ALL has severe cytopenia associated with hypoplastic marrow (marrow blast 2%) ,was referred for CART. Would you proceed with CART and reduce the lymphodepleting chemotherapy?Posted onMarch 12, 2022 2:01 pm
For a patient who achieves a morphological CR but has a persistent MRD positivity to frontline therapy- what will be your approach to therapy ?
Allo SCT or CAR-T therapyPosted onMarch 12, 2022 1:59 pm
Do you see any key differences between how paediatric patients are managed versus adolescent or young adult patients? (Alex question to Sara)Posted onMarch 12, 2022 1:55 pm
Test questionPosted onMarch 12, 2022 1:21 pm
******** Novartis *********Posted onMarch 12, 2022 1:11 pm
None of the targeted therapies in AML that I know of are curatives even in combination, or at least make a big difference in OS . My question will be, for everyone, are we in the right road to cure with new targeted therapies in AML? I'm asking myself!Posted onMarch 12, 2022 12:55 pm
Ivosidenib and Enasidenib are not avialable in europe, because they have withdrawn the licence. Do you think they will be avialable in europe in the next years?Posted onMarch 12, 2022 12:53 pm
We have a very young man with AML FLT3 positive AML, now he is in remission after 3 cycles of HiDC with haploidentical donor, we can not afford allotransplant,can we continue on Sorafinib and venetoclax maintenance...... because midaustorin nor Glitetrtinib available in Iraqi Kurdistan? Thanks...Posted onMarch 12, 2022 12:44 pm
Chemoprevention will be great sure, but don't you think using IDH inhibitors in this situation we will have at least finantial toxicity? Posted onMarch 12, 2022 12:43 pm
What is the role of auto HSCT in routine clinical practice?
Posted onMarch 12, 2022 12:42 pm
thank you very much for the great talks. I would like to ask about the use of maintenace with agents different than Azacitidine, for example FLT3 inbititors in FLT3+AML and if we have any data about the use Venetoclax (alone or in combination with HMAs) as maintenance
. Posted onMarch 12, 2022 12:42 pm
For Dra Wang : Do you have data about differences in efficacy of menin inhibitors for NPM1 mutated versus MLL-mutated? At least in vitro? Posted onMarch 12, 2022 12:40 pm
Question to dr Stein: how long do you envision that you will need to treat individuals with CCUS/CH in order to make sure that you prevent occurrence of MDS/AML? And when to stop? Based on serial IDH2 testing?Posted onMarch 12, 2022 12:39 pm
Wecan't read the pictures, there are not clear
Posted onMarch 12, 2022 12:32 pm
Many factors could be important in disease develpment and in the group of resonders with longer duration of responce for exaple for 18 monthsthat could be patient whi does not respond to therapy, or respond i CR, and the median data shows that drug works better, but this is not true for every pateint. We can say like this whe all patients will respond 18 months and drug will enlarge pateint life. Posted onMarch 12, 2022 12:29 pm
Posted onMarch 12, 2022 12:29 pm
Question to Alexander Perl: Bacause I can see the similar time for life duration between group of pateints, I wonder did you see some personal differences that are able to shorten or make patient life longer? Is is possible to incubate cancer cells with anticancer agents to check drug sensitivity. This will increase the sucess in choosing effective treatment? Posted onMarch 12, 2022 11:46 am
Posted onMarch 12, 2022 11:45 am
Were GI symptoms part of the HRQ of life questionnaire ?
Dominik Selleslag BelgiumPosted onMarch 12, 2022 11:41 am
C
Posted onMarch 12, 2022 11:10 am
** session 5 *********Posted onMarch 12, 2022 10:59 am
Can you comment 9n hiw all this can apply to chikdren with AMLPosted onMarch 12, 2022 10:46 am
If a patient is old an fit and has a p53 Mutation, should we give vyxeos instead of Aza-Ven?Posted onMarch 12, 2022 10:41 am
Patient Myelofibrosis who developed AML what is the treatment option?Posted onMarch 12, 2022 10:40 am
Are all p53 mutations equal ( homozygous, hemizygous, CN-LOH17p, ..) ? Do we have any data of response to CPX by type of p53 mutation?Posted onMarch 12, 2022 10:38 am
Question for prof. Schroeder: Do you think that also ELN good risk/more favorable AML patients could benefit from CPX-351 induction therapy instead of regular 3+7? Thank you and greetings from Jesse Tettero, Amsterdam, The Netherlands. Posted onMarch 12, 2022 10:36 am
Thanks for the great presentations to all speakers.
If you face a 70 years patient , ECOG 1-2, with no contraindication for intensive therapy but some comorbilities. Will you choose CPX or Aza-Ven? We can go for transplant either way if patient goes into RC / RCi...Posted onMarch 12, 2022 10:35 am
As we heard also yesterday the data of MRD influence to to outcome, what shall we do with the patients not achieving MRD negativity prior to Allo SCT? Another course of Chemo or go straight ahead to transplant? In Case of another course, which would you recommand? Thanks a lot!Posted onMarch 12, 2022 10:28 am
Jazz *****************Posted onMarch 12, 2022 8:32 am
********** Day 3 **********Posted onMarch 12, 2022 8:32 am
Great talk, thank you!Posted onMarch 11, 2022 5:13 pm
For patients with good risk AML and MRD Positivity after Induktion, would you plan an allograft or keep on with consolidation?Posted onMarch 11, 2022 5:08 pm
Question for Roland, how do you use MRD results for choosing consolidation therapy? Also regarding ELN-risk classification. Thank you, greetings Jesse Tettero, Amsterdam The NetherlandsPosted onMarch 11, 2022 5:01 pm
thank you very much!
if after achieving MRD negativity in a patient with BCR-ABL+ ALL on mantainance with a TKI we encounter an in icrease in BCR-ABL copies would you try to switch to an other TKI at first or you would directly treat the patient as a relapse-ALL. Posted onMarch 11, 2022 4:57 pm
if B-ALL relapse after MSD- allo HSCT achieved MRD neg ( FCM ) after CART cell , what do you do? if there is no circulating CART cell ?
if you do a second Allo, can u use the same donor?Posted onMarch 11, 2022 4:57 pm
Roland : any thoughts how to improve outcome prediction by MRD?
Gert OssenkoppelePosted onMarch 11, 2022 4:33 pm
******* Roundtable 1 ********Posted onMarch 11, 2022 4:18 pm
WHAT ABOUT CHEMO + VENETOCLAX FOR P53 POSITIV PTS?Posted onMarch 11, 2022 4:12 pm
Both of you mentioned a couple of times that randomized studies are lacking. We have to be realistic with so many new posibilities and combinations of new drugs that for most questions we have to rEly on RWD. If numbers in registrations are high propensity analysis can be helpful and replace randomization. ALTHOUGH randomized PHASE III TRIALS ARE THE GOLD STANDARD we have rely in part on RWD.Do you agree? GERT OSSENKOPPELE
Gert OssenkoppelePosted onMarch 11, 2022 4:08 pm
would you suggest higher dose venetoclax (600 mg, 800 mg) for P53 AML to sustain remission?
Posted onMarch 11, 2022 4:07 pm
About the use of HAPLO transplants post VEN -AZA the results is the same as the use of ALLO with Full matsh donor on that group of patients ?Posted onMarch 11, 2022 4:04 pm
About the use of HAPLO transplants post VEN -AZA the results is the same as the use of ALLO with Full matsh donor on that group of patients ?Posted onMarch 11, 2022 4:04 pm
Since Venetoclax does not work in Tp53 positive Patients, shall we give the older fit ones only aza or intensive chemo?Posted onMarch 11, 2022 4:03 pm
Posted onMarch 11, 2022 3:58 pm
FLT-3 post allo who is MRD neg preAllo: do you still give sorafenib esp if the patient has GvHDPosted onMarch 11, 2022 3:58 pm
MRD assessment by different methods and with reference to a subgroup of AML, how it differs, and how to utilize in clinical practice?Posted onMarch 11, 2022 3:56 pm
thank you for the great presentations. I would like to ask: for a fit patient with poor cytogenetics who is inelligible for alloSCT (eg no donors, ect) would you give a try to intensive chemotherapy of start with VenAzaPosted onMarch 11, 2022 3:56 pm
In fact quit a number of fit elderly in CR after chemo do not make it to an alloSCT. hy not maintain with HMA/AZA as maitenance has been shown effective in the Quazar trial.
Gert OssenkoppelePosted onMarch 11, 2022 3:55 pm
For both of the speakers in the debate
If you bridge an older patient to an allo after HMA/ Ven , what do you use for post transplant maintenance?
Especially if patient is MRD positive going into transplant
Raj Nath
Phoenix Posted onMarch 11, 2022 3:50 pm
For both of the speakers in the debate
If you bridge an older patient to an allo after HMA/ Ven , what do you use for post transplant maintenance?
Especially if patient is MRD positive going into transplant
Raj Nath
Phoenix Posted onMarch 11, 2022 3:50 pm
Which option would be best for an older fit patient who progresses to AML after MDS treated with azacitidine?Posted onMarch 11, 2022 3:50 pm
For Courtney. What about countries where fox is reimbursed only for mrc aml?
Posted onMarch 11, 2022 3:49 pm
Please some comments about the intensity of consolidation in elderly fit patients who started treatment
with intensive chemo?Posted onMarch 11, 2022 3:44 pm
we are only talking about the combination of ven-aza, how about a combination of decitabine-ven? Posted onMarch 11, 2022 3:40 pm
Posted onMarch 11, 2022 3:39 pm
******* Debate ********Posted onMarch 11, 2022 3:25 pm
We can't see anything
Posted onMarch 11, 2022 3:23 pm
we can not see your screenPosted onMarch 11, 2022 3:23 pm
Flt-3 patient post allo HSCT : (1) what is the best MRD test strategy, (2) post allo HSCT who is MRD negative ; role of maintenancePosted onMarch 11, 2022 3:08 pm
we have a fit 78 year old patient (no comorbidities) with p53 AML who achieved MRD Negativity with Decitabin and Venetclax, would you transplant her?Posted onMarch 11, 2022 3:04 pm
A fit patient with p53 mutant patient who has achieved MRD negative with no sibling donor, how to manage this patient?Posted onMarch 11, 2022 2:53 pm
Jean Catapia,Philippines: With the lecture of Dr. Guillermo Ramil, would you recommend that patients with higher TRM scores be started with GCSF during the nadir of counts?Posted onMarch 11, 2022 2:49 pm
Is MRD 10-3 of VIALE-A sufficient enough, meaning negative, to proceed to transplant? (Ioanna - Greece)
Posted onMarch 11, 2022 2:48 pm
Please keep in mind that either enasidenib and ivosidenib are not avialable in europe because the application for admission has been withdrawnPosted onMarch 11, 2022 2:31 pm
Posted onMarch 11, 2022 2:25 pm
Posted onMarch 11, 2022 2:25 pm
Posted onMarch 11, 2022 2:25 pm
what is the good regime for relapsed patient with simultaneous IDH1 and FLT3-ITD mutation?Posted onMarch 11, 2022 2:06 pm
Although aware of dismal prognosis, could we try LDAC+glasdegib as 3rd line, hoping new treatment mechanism can help?Posted onMarch 11, 2022 1:40 pm
Why is Aza-Ven considered a non (less) intensive treatment in relation to 3+7' ? (mortality, duration of neutropenia, infections ?)
Dr. Billio-ItalyPosted onMarch 11, 2022 1:35 pm
Posted onMarch 11, 2022 1:22 pm
**** Session 3 *****Posted onMarch 11, 2022 1:04 pm
******** BMS ********Posted onMarch 11, 2022 12:49 pm
Can this type of treatments be used to allow patients to recover from serious adverse events during standard treatment to then resume chemotherapy later, maybe even months later?Posted onMarch 11, 2022 12:44 pm
1. Aza-ven, At Day 21 or 28 of C1 I stop venetoclax because patient is pancytopenic and has no blasts on BM and I wait for recovery with GCSF. Which attitude if the patient doesn' recovery after 14 days? New BM and wait if still remission? Start C2 without checking BM despite pancytopenia?
2. Some patients with aza-ven have still blasts excess after C2 but anyway they have a clinical benefit from the treatment (reduction transfusions need): still a hope for 'late response' after 4-6 cycles?
Thank you (Fabio Belgium) Posted onMarch 11, 2022 12:26 pm
Posted onMarch 11, 2022 12:10 pm
Posted onMarch 11, 2022 8:28 am
Posted onMarch 11, 2022 8:28 am
Does this protein folding process correlates with the phosphorylation of the receptor? (Ioanna Greece). Too late... Posted onMarch 10, 2022 6:35 pm
Posted onMarch 10, 2022 6:05 pm
******* Poster ***Posted onMarch 10, 2022 6:05 pm
For post allogeneic Allo-HSCT FLT- positive AML , what methods of MRD and the timing of MRD tests, in your routine clinical practice?
Do you use MRD to decide on maintenance therapy for AML after allo HSCT?Posted onMarch 10, 2022 5:43 pm
Dr. Sylvie Freeman:
If a patient with NPM1-mutated AML has a molecular relapse after treatment, will you wait for the hematologic relapse to treat or would you do salvage chemo/allo-transplant?
Thank you!Posted onMarch 10, 2022 5:15 pm
Prof. Venditti:
In an intermediate-risk AML patient with NPM1+ and FLT3-ITD+ high allelic ratio with negative MRD, would an autologous transplant followed by midostaurin maintenance be an option? Or would 1-year maintenance with midostaurin be a better option?Posted onMarch 10, 2022 5:14 pm
Silvia Jimenez, Mexico, what do the experts think about the use of circulating miRNAs to assess MRD, is it feasible?Posted onMarch 10, 2022 5:09 pm
2Posted onMarch 10, 2022 5:02 pm
Jorge Illarramendi Spain: We recently treat a patient with 3+7 and VO and he suffered sinusoidal obstruction syndrome. You will continue with VO in the next cycle. Thank youPosted onMarch 10, 2022 4:56 pm
Laurent Dewispelaere (Belgium): To Jan, did you compare your IGH/TCR MRD results to commercial NGS methods (f.e. Invivoscribe Lymphotrack)? Posted onMarch 10, 2022 4:44 pm
to Sylvie: How many cells do you analyse for Flow MRD?Posted onMarch 10, 2022 4:30 pm
****** Session 2 *********Posted onMarch 10, 2022 4:00 pm
ThanksPosted onMarch 10, 2022 3:59 pm
to Marielle: How do you treat Patients with MPAL who are Bcr-Abl positive? Posted onMarch 10, 2022 3:51 pm
Posted onMarch 10, 2022 3:42 pm
Can oxford nanopore sequencing replace the conventional cytogenetics?
Dr SanjeevPosted onMarch 10, 2022 3:41 pm
I would like to ask the pannel two questions about maintenance treatment in ALL.
First if the there is any data about the ideal TKI mantainance in BCR-ABL+ ALL (especially after AlloSCT) and secondly if there are is any maintenace treatment for T-ALL Posted onMarch 10, 2022 3:39 pm
Can we have ETP ALL without expression of CD34/CD117/TdT or any other stem cell marker?Posted onMarch 10, 2022 3:30 pm
Should all patients with T-ALL be consolidated with allogeneic stem cell transplant if eligible?Posted onMarch 10, 2022 3:26 pm
.Posted onMarch 10, 2022 3:26 pm
Q to Dr Wendy Stock:
Does ETP diagnosis need both stem cell and myeloid markers?
As per the IPT definition, isn't it stem and/or myeloid with other defining feature like cCD3 but CD5 dim/absent, CD8-, CD1a-
Thanks
Dr Sanjeev Gupta (India)Posted onMarch 10, 2022 3:12 pm
H. Dombret (Paris): Given its T-cell suppressive effect, is ruxolitinib contra-indicated in combination with T-cell engaging drugs?Posted onMarch 10, 2022 3:04 pm
D
Posted onMarch 10, 2022 3:00 pm
Posted onMarch 10, 2022 2:57 pm
BPosted onMarch 10, 2022 2:57 pm
How often should we administer CNS prophylaxis via IT in MPAL with t(9;22) before allo-transplant?
Thank you,
Joana - PortugalPosted onMarch 10, 2022 2:53 pm
D Dr Sanjeev Gupta IndiaPosted onMarch 10, 2022 2:53 pm
ABL sequencing will allow knowing that optimal ITKPosted onMarch 10, 2022 2:52 pm
DPosted onMarch 10, 2022 2:52 pm
a
Posted onMarch 10, 2022 2:52 pm
Posted onMarch 10, 2022 2:52 pm
Hello! My livestream is freezing. Is there a chance to fix that?
Posted onMarch 10, 2022 2:38 pm
I would like to ask Elli Papaemmanouil: The combination of WT1 mutation with NPM1 mutation in AML has been proposed as an adverse risk combination by some recent opinions. Have you reached the same conclusion in your research? Congratulations for your great work and talk (Michael Diamantidis, Greece)Posted onMarch 10, 2022 2:35 pm
Do you think it is important to analyze the allelic affectation of TP53 for differential prognosis? If it is mono or biallelic? Thank you. Neus Ruiz, SpainPosted onMarch 10, 2022 2:33 pm
Question for Dr.Papaemmanuil: Allelic ratio of FLT3-ITD (low/high) most probably will be removed from the new ELN classification, but what about the the insertion site? There are data that patients with insertion limited in the juxtamembrane region do benefit from the addition of FLT3 inhibitors, whereas TKD1sole insertion and JMD/TKD1 insertion revealed as an unfavorable prognostic factor for OS and CIR in the RATIFY trial. Could insertion site further distinguish FLT3 patients and change treatment strategy? (e.g. transplantation in CR1 or not?) (Ioanna - Greece)Posted onMarch 10, 2022 2:33 pm
Posted onMarch 10, 2022 2:33 pm
Great talk. Would you please elaborate on the pros/cons of long read Nanopore seq. for karyotyping as opposed to SNParray? Thank you! Elsa BernardPosted onMarch 10, 2022 2:31 pm
To Prof. Bullinger: why did you not decide to do an allogenous Transplant to this patient with his high risk MDS befor he developes an AML? (Joanna Germany)Posted onMarch 10, 2022 2:27 pm
Posted onMarch 10, 2022 2:21 pm
Excellent work! sAML1and sAML2 subgroups being defined by the number of sAML-like mutations only (not the genes), this sub-discrimination doesn't not allow capturing the relative impact of each sAML-like gene taken individually. How these genes were distributed among the two groups?Posted onMarch 10, 2022 2:13 pm
Laurent Dewispealere (Belgium): Did you analyze the impact of single BZIP CEBPA mutation compared to biallelic CEBPA mutation in prognosis stratification? Posted onMarch 10, 2022 2:12 pm
***** Session 1 ********Posted onMarch 10, 2022 1:53 pm
With sequencing today many genetic alterations with specific white drugs are known. However, many do not achieve long survival. Do I have to increase medications?Posted onMarch 10, 2022 1:52 pm
Do you believe that PCR for FLT3-ITD detection will still be around even in the advent of WGS? (Ioanna - Greece)Posted onMarch 10, 2022 1:47 pm
not heardPosted onMarch 10, 2022 1:47 pm
Posted onMarch 10, 2022 1:46 pm
Xiao-Hua Luo(China): Most of AML patients have more mutations than gene fusions considering the age of this disease. Is it possible to weight the mutations and gene fusions for the prognosis and treatment program in your method?Posted onMarch 10, 2022 1:46 pm
Xiao-Hua Luo(China): Most of AML patients have more mutations than gene fusions considering the age of this disease. Is it possible to weight the mutations and gene fusions for the prognosis and treatment program in your method?Posted onMarch 10, 2022 1:46 pm
Thank you for this great talk! Were there any cases, to your knowledge, when WGS/NGS failed to detect mutations, and classical cytogenetics did? Could they be considered complementary methods? Dr. Zelic, CroatiaPosted onMarch 10, 2022 1:46 pm
Laurent Dewispelaere (Belgium). Does your cost analysis include personnel cost (both technician and analyst/geneticists)? Considering how labor intensive cytogenetics is compared to WGS, the latter could already be a valid alternative for cancer centers.Posted onMarch 10, 2022 1:46 pm
Thank you Dr Spencer, very interesting! Have you add any findings that were ambiguous for the origin of the mutation (somatic or germline) ? And cases where you would have benefited from adding a germline control ?
Alexandre Rouette, CHU Sainte-Justine, Montreal, CanadaPosted onMarch 10, 2022 1:44 pm
Antonio Galleu, Italy: can you elaborate on the same OS observed for intermediate group and good risk group? Posted onMarch 10, 2022 1:41 pm
How soon do you consider that this methodology can be largely adapted, mainly outside academic centers and the US? And will the data alter finally the ELN risk classification based on co-mutations? (Ioanna - Greece)Posted onMarch 10, 2022 1:29 pm
How soon do you consider that this methodology can be largely adapted, mainly outside academic centers and the US? And will the data alter finally the ELN risk classification based on co-mutations? (Ioanna - Greece)Posted onMarch 10, 2022 1:29 pm
Posted onMarch 10, 2022 1:20 pm
Posted onMarch 10, 2022 1:20 pm
keynote
Posted onMarch 10, 2022 1:16 pm
Posted onMarch 10, 2022 9:58 am
Testing 123Posted onMarch 10, 2022 8:09 am
testingPosted onMarch 9, 2022 10:13 pm
***Posted onMarch 16, 2022 8:06 am
THanks. Virgilio Alberto Salinas Rodríguez from Peru (2011898 EBAH) appreciates allowing attendance at E-conference 3ed How to diagnose and treat acute leukemias. Posted onMarch 13, 2022 11:31 am
Thank you very much for this exciting meeting! Jelena RoganovicPosted onMarch 13, 2022 11:30 am
In few months oral AZA will be available as mantainance in not transplanted patients. Could this change the indication to Tx in NPM1 pos patients?Posted onMarch 13, 2022 11:23 am
Kimmo :Did you observe MRD negative responses? Could you deliver Ven in the 400mg dosage or had you adapt the dosage Gert OssenkoppelePosted onMarch 13, 2022 11:17 am
Kimmo :Did you observe MRD negative responses? Could you deliver Ven in the 400mg dosage or had you adapt the dosage Gert OssenkoppelePosted onMarch 13, 2022 11:17 am
Thank you for a fantastic series of talks.. three questions/comments: A) The UK NCRI Group is studying post-transplant maintenance CC486 in patients allografted for AML. Currently 230 patients recruited through the IMPACT trials network. Study closure anticipated Q3 2022 B) Could Anneke comment on timing of immunosuppression withdrawal in patients allografted for high risk AML/MDS noting that in the case study the patient was still on immunosuppression at 6 months post-transplant C) Could Rafael specifically comment on indications for transplant in older patients (>60) with AML in CR1 noting the v high risk of relapse using chemo alone in this group and the fact that some predictors eg NPM1 may not apply in older patients Thanks again! Charlie Craddock BirminghamPosted onMarch 13, 2022 11:16 am
what is the best treatment for steroid-refractory LIver GvHDPosted onMarch 13, 2022 11:16 am
how do you treat Sclerodema like (skin, fascia, muscle) chronic GvHD?Posted onMarch 13, 2022 11:14 am
How could The availability of oral AZA maintenance integrate the proposed flow chart decision about Allogeneic SCT in 1st CR in NPM1pos AMLPosted onMarch 13, 2022 11:10 am
Question for Prof Zeiser from Giorgia Battipaglia, Italy: in pts obtaining RP after ruxolitinib for SR-aGVHD, which drug(s) do you suggest? ThanksPosted onMarch 13, 2022 11:09 am
to Dr. Zeiser: you focused mainly on Ruxolitinib, how are these results compared to ECP for treatment of SR a- or c-GvHD?Posted onMarch 13, 2022 10:40 am
Why don,t stopp immediatly cyclosporin or fks Posted onMarch 13, 2022 9:53 am
Posted onMarch 13, 2022 9:42 am
Posted onMarch 13, 2022 9:42 am
What is the difference in toxicity (first induction cycle) between "intensive therapy" vs AZA-ven?Posted onMarch 13, 2022 9:42 am
Posted onMarch 13, 2022 9:08 am
The issue of oligoclonality in MLL rearranged patients is addressed in Europe by MLL breakpoint mapping and ASO assay design specific to the MLL rearrangement. This is needed for MRD monitoring and risk stratification in infant ALL. How is this managed in the USA?Posted onMarch 13, 2022 9:03 am
********* Day 4 *************Posted onMarch 13, 2022 8:56 am
Do you think that MRD assessment is clinically applicable in most patients >65y.o. for whom treatment options are more limited?Posted onMarch 13, 2022 8:28 am
Can clonoseq be used on DNA from FFPE material taken at diagnosis if the clinicians did not take a fresh sample for MRD target identification?Posted onMarch 13, 2022 8:26 am
A young patient with refractory relapse (post auto HSCT) Primary B cell lymphoma who achieved PR with Pembrolizumab based therapy went on to receive CART therapy. PET CT after one month of CART showed no reduction in the tumor. The CART cell were not detectable in the blood after infusion. What is the best option for this patient? A second CAR-T (?? at higher dose, ? combination with a PD-1 inhibitor. or sequential infusion of CAR-T ? He has no matched sibling donor.Posted onMarch 12, 2022 6:18 pm
to N Gökbuget : do you still consider chemotherapy for first relapse in Ph-neg ALL patient? If yes, in which cases?Posted onMarch 12, 2022 5:16 pm
Is blinatutmumab contraindicated in initial parkinson's disease?Posted onMarch 12, 2022 5:08 pm
we can not see the slides!Posted onMarch 12, 2022 4:58 pm
Thanks for correcting the clarity :)Posted onMarch 12, 2022 4:55 pm
resolved. Just want to mention that the screen appears blurred for this talk compared to previous. Posted onMarch 12, 2022 4:52 pm
the screen is still. No movement since Q3 posted. Posted onMarch 12, 2022 4:49 pm
Posted onMarch 12, 2022 4:45 pm
******* Session 5 **********Posted onMarch 12, 2022 4:38 pm
if a patient has severe cytopenia and BM hypoplasia (BM blast 2%) and oral GvHD, should the patients receive CART and if yes, should the dose of the lymphodepletion be reduced? are these factors going to reduce the efficacy of CAR-t? Posted onMarch 12, 2022 4:28 pm
CAR T cell is an alternative to locate unrelated HLA donorPosted onMarch 12, 2022 4:24 pm
CAR T cell 19/22 has benefit over CAR T cell 19 or CAR T cell 22Posted onMarch 12, 2022 4:22 pm
if there is no circulating CART at day 7 and day 14 after CART infusion, is there a role to repeat the infusion? Is there a role of sequential infusion (Day 0, Day 15 or day 21)? What can be done to improve the expansion and persistence? What is the level of PB CART that is acceptable to improve the clinical outcome?Posted onMarch 12, 2022 4:22 pm
Does prior CAR T-Cell therapy affect post-transplant complications? (M. Sevki Uyanik, Turkey)Posted onMarch 12, 2022 4:19 pm
Thanks for the nice presentations. Do you think that a null tumor burden (EMR negative) such as that achieved with immunotherapy such as inotuzumab, is a risk of post-CART relapse, and should be a risk to be taken into account when deciding on post-Cart ALLoTPH?Posted onMarch 12, 2022 4:16 pm
Beautiful music! :)Posted onMarch 12, 2022 3:39 pm
****** Debate 2 *********Posted onMarch 12, 2022 3:36 pm
ThanksPosted onMarch 12, 2022 3:32 pm
how do you select patient (no donor) that is suitable for autoHSCT?Posted onMarch 12, 2022 3:31 pm
Posted onMarch 12, 2022 3:29 pm
For post ALLO HSCT maintenance which TKI is the most appropriate?Posted onMarch 12, 2022 3:29 pm
maintenance Prednisone 200 mg for 4 days every 15 days, methotrexate 20 mg/m2 day 14 and imatinib 600 mg daily for 15 days. Maintain patient with ALL Ph positive with negative MRD.Posted onMarch 12, 2022 3:29 pm
KZF1 how do I diagnosePosted onMarch 12, 2022 3:22 pm
Ponatinib produce efecto cardiovascular que se ve en LMCPosted onMarch 12, 2022 3:21 pm
In the german guidelines BCR-ABL patients pos. patients are predicted high-risk and should recieve Allo SCT, after these results, would you still recommend that?Posted onMarch 12, 2022 3:19 pm
thank you very much! I would like to ask, for a Ph+ALL patient that underwent alloSCT would you continue a maintenance treatment with a TKI and when would be the best timing (due to drug interactions)? Posted onMarch 12, 2022 3:16 pm
thank you very much! I would like to ask, for a Ph+ALL patient that underwent alloSCT would you continue a maintenance treatment with a TKI and when would be the best timing (due to drug interactions)? Posted onMarch 12, 2022 3:16 pm
thank you very much! I would like to ask, for a Ph+ALL patient that underwent alloSCT would you continue a maintenance treatment with a TKI and when would be the best timing (due to drug interactions)? Posted onMarch 12, 2022 3:16 pm
How frequently have you seen that bcr-abl is negative by PCR but NGS MRD is positive? What is your approach to those patients?Posted onMarch 12, 2022 3:12 pm
What is the best method to monitor MRD: BCR-ABL PCR, IgTCR PCR or NGS?Posted onMarch 12, 2022 3:10 pm
For ALL Ph positive after finishing of both arms of Hyper-CVAD plus ponatinib, for maintenance, can we give for maintenance 6MP, MTX, ONCOVIN WITH PONATINIB FOR 16 months or 2 years? Posted onMarch 12, 2022 3:04 pm
To Sabina Chiaretti: Thank you for your excellent talk. What kind of MRD do you think is more reliable to decide to transplant patients with Ph+ ALL : BCR-ABL or IG/TR ?Posted onMarch 12, 2022 2:55 pm
**** Rounudtable 2 ***********Posted onMarch 12, 2022 2:19 pm
Do you think targeting leukemic stem cells+ B-cell antigen through CAR-T therapy may have better outcome and persistence of response? Dr Zafar Iqbal, Pakistan Posted onMarch 12, 2022 2:09 pm
Posted onMarch 12, 2022 2:09 pm
Looks like B cell aphasia is being used as a surrogate of persistent of CAR-T cells, is there real word data on persistence of CARs and long term outcomes?Posted onMarch 12, 2022 2:08 pm
If B-ALL relapse post ALLO- HSCT, patient achieved Flow- MRD negative after CART cell but the CART became undetectable, would you do a second AlloHCT? or give another CART?Posted onMarch 12, 2022 2:08 pm
For a patient with relapsed or refractory ALL to chemotherapy, you would prefer CART or blinatumomab prior alloSCTPosted onMarch 12, 2022 2:04 pm
Is there any data regarding outcome of CAR-T therapy after first negative MRD? Dr Zafar Iqbal, Pakistan. Posted onMarch 12, 2022 2:01 pm
if patient with post HSCT relapse B-ALL has severe cytopenia associated with hypoplastic marrow (marrow blast 2%) ,was referred for CART. Would you proceed with CART and reduce the lymphodepleting chemotherapy?Posted onMarch 12, 2022 2:01 pm
For a patient who achieves a morphological CR but has a persistent MRD positivity to frontline therapy- what will be your approach to therapy ? Allo SCT or CAR-T therapyPosted onMarch 12, 2022 1:59 pm
Do you see any key differences between how paediatric patients are managed versus adolescent or young adult patients? (Alex question to Sara)Posted onMarch 12, 2022 1:55 pm
Test questionPosted onMarch 12, 2022 1:21 pm
******** Novartis *********Posted onMarch 12, 2022 1:11 pm
None of the targeted therapies in AML that I know of are curatives even in combination, or at least make a big difference in OS . My question will be, for everyone, are we in the right road to cure with new targeted therapies in AML? I'm asking myself!Posted onMarch 12, 2022 12:55 pm
Ivosidenib and Enasidenib are not avialable in europe, because they have withdrawn the licence. Do you think they will be avialable in europe in the next years?Posted onMarch 12, 2022 12:53 pm
We have a very young man with AML FLT3 positive AML, now he is in remission after 3 cycles of HiDC with haploidentical donor, we can not afford allotransplant,can we continue on Sorafinib and venetoclax maintenance...... because midaustorin nor Glitetrtinib available in Iraqi Kurdistan? Thanks...Posted onMarch 12, 2022 12:44 pm
Chemoprevention will be great sure, but don't you think using IDH inhibitors in this situation we will have at least finantial toxicity? Posted onMarch 12, 2022 12:43 pm
What is the role of auto HSCT in routine clinical practice? Posted onMarch 12, 2022 12:42 pm
thank you very much for the great talks. I would like to ask about the use of maintenace with agents different than Azacitidine, for example FLT3 inbititors in FLT3+AML and if we have any data about the use Venetoclax (alone or in combination with HMAs) as maintenance . Posted onMarch 12, 2022 12:42 pm
For Dra Wang : Do you have data about differences in efficacy of menin inhibitors for NPM1 mutated versus MLL-mutated? At least in vitro? Posted onMarch 12, 2022 12:40 pm
Question to dr Stein: how long do you envision that you will need to treat individuals with CCUS/CH in order to make sure that you prevent occurrence of MDS/AML? And when to stop? Based on serial IDH2 testing?Posted onMarch 12, 2022 12:39 pm
Wecan't read the pictures, there are not clear Posted onMarch 12, 2022 12:32 pm
Many factors could be important in disease develpment and in the group of resonders with longer duration of responce for exaple for 18 monthsthat could be patient whi does not respond to therapy, or respond i CR, and the median data shows that drug works better, but this is not true for every pateint. We can say like this whe all patients will respond 18 months and drug will enlarge pateint life. Posted onMarch 12, 2022 12:29 pm
Posted onMarch 12, 2022 12:29 pm
Question to Alexander Perl: Bacause I can see the similar time for life duration between group of pateints, I wonder did you see some personal differences that are able to shorten or make patient life longer? Is is possible to incubate cancer cells with anticancer agents to check drug sensitivity. This will increase the sucess in choosing effective treatment? Posted onMarch 12, 2022 11:46 am
Posted onMarch 12, 2022 11:45 am
Were GI symptoms part of the HRQ of life questionnaire ? Dominik Selleslag BelgiumPosted onMarch 12, 2022 11:41 am
C Posted onMarch 12, 2022 11:10 am
** session 5 *********Posted onMarch 12, 2022 10:59 am
Can you comment 9n hiw all this can apply to chikdren with AMLPosted onMarch 12, 2022 10:46 am
If a patient is old an fit and has a p53 Mutation, should we give vyxeos instead of Aza-Ven?Posted onMarch 12, 2022 10:41 am
Patient Myelofibrosis who developed AML what is the treatment option?Posted onMarch 12, 2022 10:40 am
Are all p53 mutations equal ( homozygous, hemizygous, CN-LOH17p, ..) ? Do we have any data of response to CPX by type of p53 mutation?Posted onMarch 12, 2022 10:38 am
Question for prof. Schroeder: Do you think that also ELN good risk/more favorable AML patients could benefit from CPX-351 induction therapy instead of regular 3+7? Thank you and greetings from Jesse Tettero, Amsterdam, The Netherlands. Posted onMarch 12, 2022 10:36 am
Thanks for the great presentations to all speakers. If you face a 70 years patient , ECOG 1-2, with no contraindication for intensive therapy but some comorbilities. Will you choose CPX or Aza-Ven? We can go for transplant either way if patient goes into RC / RCi...Posted onMarch 12, 2022 10:35 am
As we heard also yesterday the data of MRD influence to to outcome, what shall we do with the patients not achieving MRD negativity prior to Allo SCT? Another course of Chemo or go straight ahead to transplant? In Case of another course, which would you recommand? Thanks a lot!Posted onMarch 12, 2022 10:28 am
Jazz *****************Posted onMarch 12, 2022 8:32 am
********** Day 3 **********Posted onMarch 12, 2022 8:32 am
Great talk, thank you!Posted onMarch 11, 2022 5:13 pm
For patients with good risk AML and MRD Positivity after Induktion, would you plan an allograft or keep on with consolidation?Posted onMarch 11, 2022 5:08 pm
Question for Roland, how do you use MRD results for choosing consolidation therapy? Also regarding ELN-risk classification. Thank you, greetings Jesse Tettero, Amsterdam The NetherlandsPosted onMarch 11, 2022 5:01 pm
thank you very much! if after achieving MRD negativity in a patient with BCR-ABL+ ALL on mantainance with a TKI we encounter an in icrease in BCR-ABL copies would you try to switch to an other TKI at first or you would directly treat the patient as a relapse-ALL. Posted onMarch 11, 2022 4:57 pm
if B-ALL relapse after MSD- allo HSCT achieved MRD neg ( FCM ) after CART cell , what do you do? if there is no circulating CART cell ? if you do a second Allo, can u use the same donor?Posted onMarch 11, 2022 4:57 pm
Roland : any thoughts how to improve outcome prediction by MRD? Gert OssenkoppelePosted onMarch 11, 2022 4:33 pm
******* Roundtable 1 ********Posted onMarch 11, 2022 4:18 pm
WHAT ABOUT CHEMO + VENETOCLAX FOR P53 POSITIV PTS?Posted onMarch 11, 2022 4:12 pm
Both of you mentioned a couple of times that randomized studies are lacking. We have to be realistic with so many new posibilities and combinations of new drugs that for most questions we have to rEly on RWD. If numbers in registrations are high propensity analysis can be helpful and replace randomization. ALTHOUGH randomized PHASE III TRIALS ARE THE GOLD STANDARD we have rely in part on RWD.Do you agree? GERT OSSENKOPPELE Gert OssenkoppelePosted onMarch 11, 2022 4:08 pm
would you suggest higher dose venetoclax (600 mg, 800 mg) for P53 AML to sustain remission? Posted onMarch 11, 2022 4:07 pm
About the use of HAPLO transplants post VEN -AZA the results is the same as the use of ALLO with Full matsh donor on that group of patients ?Posted onMarch 11, 2022 4:04 pm
About the use of HAPLO transplants post VEN -AZA the results is the same as the use of ALLO with Full matsh donor on that group of patients ?Posted onMarch 11, 2022 4:04 pm
Since Venetoclax does not work in Tp53 positive Patients, shall we give the older fit ones only aza or intensive chemo?Posted onMarch 11, 2022 4:03 pm
Posted onMarch 11, 2022 3:58 pm
FLT-3 post allo who is MRD neg preAllo: do you still give sorafenib esp if the patient has GvHDPosted onMarch 11, 2022 3:58 pm
MRD assessment by different methods and with reference to a subgroup of AML, how it differs, and how to utilize in clinical practice?Posted onMarch 11, 2022 3:56 pm
thank you for the great presentations. I would like to ask: for a fit patient with poor cytogenetics who is inelligible for alloSCT (eg no donors, ect) would you give a try to intensive chemotherapy of start with VenAzaPosted onMarch 11, 2022 3:56 pm
In fact quit a number of fit elderly in CR after chemo do not make it to an alloSCT. hy not maintain with HMA/AZA as maitenance has been shown effective in the Quazar trial. Gert OssenkoppelePosted onMarch 11, 2022 3:55 pm
For both of the speakers in the debate If you bridge an older patient to an allo after HMA/ Ven , what do you use for post transplant maintenance? Especially if patient is MRD positive going into transplant Raj Nath Phoenix Posted onMarch 11, 2022 3:50 pm
For both of the speakers in the debate If you bridge an older patient to an allo after HMA/ Ven , what do you use for post transplant maintenance? Especially if patient is MRD positive going into transplant Raj Nath Phoenix Posted onMarch 11, 2022 3:50 pm
Which option would be best for an older fit patient who progresses to AML after MDS treated with azacitidine?Posted onMarch 11, 2022 3:50 pm
For Courtney. What about countries where fox is reimbursed only for mrc aml? Posted onMarch 11, 2022 3:49 pm
Please some comments about the intensity of consolidation in elderly fit patients who started treatment with intensive chemo?Posted onMarch 11, 2022 3:44 pm
we are only talking about the combination of ven-aza, how about a combination of decitabine-ven? Posted onMarch 11, 2022 3:40 pm
Posted onMarch 11, 2022 3:39 pm
******* Debate ********Posted onMarch 11, 2022 3:25 pm
We can't see anything Posted onMarch 11, 2022 3:23 pm
we can not see your screenPosted onMarch 11, 2022 3:23 pm
Flt-3 patient post allo HSCT : (1) what is the best MRD test strategy, (2) post allo HSCT who is MRD negative ; role of maintenancePosted onMarch 11, 2022 3:08 pm
we have a fit 78 year old patient (no comorbidities) with p53 AML who achieved MRD Negativity with Decitabin and Venetclax, would you transplant her?Posted onMarch 11, 2022 3:04 pm
A fit patient with p53 mutant patient who has achieved MRD negative with no sibling donor, how to manage this patient?Posted onMarch 11, 2022 2:53 pm
Jean Catapia,Philippines: With the lecture of Dr. Guillermo Ramil, would you recommend that patients with higher TRM scores be started with GCSF during the nadir of counts?Posted onMarch 11, 2022 2:49 pm
Is MRD 10-3 of VIALE-A sufficient enough, meaning negative, to proceed to transplant? (Ioanna - Greece) Posted onMarch 11, 2022 2:48 pm
Please keep in mind that either enasidenib and ivosidenib are not avialable in europe because the application for admission has been withdrawnPosted onMarch 11, 2022 2:31 pm
Posted onMarch 11, 2022 2:25 pm
Posted onMarch 11, 2022 2:25 pm
Posted onMarch 11, 2022 2:25 pm
what is the good regime for relapsed patient with simultaneous IDH1 and FLT3-ITD mutation?Posted onMarch 11, 2022 2:06 pm
Although aware of dismal prognosis, could we try LDAC+glasdegib as 3rd line, hoping new treatment mechanism can help?Posted onMarch 11, 2022 1:40 pm
Why is Aza-Ven considered a non (less) intensive treatment in relation to 3+7' ? (mortality, duration of neutropenia, infections ?) Dr. Billio-ItalyPosted onMarch 11, 2022 1:35 pm
Posted onMarch 11, 2022 1:22 pm
**** Session 3 *****Posted onMarch 11, 2022 1:04 pm
******** BMS ********Posted onMarch 11, 2022 12:49 pm
Can this type of treatments be used to allow patients to recover from serious adverse events during standard treatment to then resume chemotherapy later, maybe even months later?Posted onMarch 11, 2022 12:44 pm
1. Aza-ven, At Day 21 or 28 of C1 I stop venetoclax because patient is pancytopenic and has no blasts on BM and I wait for recovery with GCSF. Which attitude if the patient doesn' recovery after 14 days? New BM and wait if still remission? Start C2 without checking BM despite pancytopenia? 2. Some patients with aza-ven have still blasts excess after C2 but anyway they have a clinical benefit from the treatment (reduction transfusions need): still a hope for 'late response' after 4-6 cycles? Thank you (Fabio Belgium) Posted onMarch 11, 2022 12:26 pm
Posted onMarch 11, 2022 12:10 pm
Posted onMarch 11, 2022 8:28 am
Posted onMarch 11, 2022 8:28 am
Does this protein folding process correlates with the phosphorylation of the receptor? (Ioanna Greece). Too late... Posted onMarch 10, 2022 6:35 pm
Posted onMarch 10, 2022 6:05 pm
******* Poster ***Posted onMarch 10, 2022 6:05 pm
For post allogeneic Allo-HSCT FLT- positive AML , what methods of MRD and the timing of MRD tests, in your routine clinical practice? Do you use MRD to decide on maintenance therapy for AML after allo HSCT?Posted onMarch 10, 2022 5:43 pm
Dr. Sylvie Freeman: If a patient with NPM1-mutated AML has a molecular relapse after treatment, will you wait for the hematologic relapse to treat or would you do salvage chemo/allo-transplant? Thank you!Posted onMarch 10, 2022 5:15 pm
Prof. Venditti: In an intermediate-risk AML patient with NPM1+ and FLT3-ITD+ high allelic ratio with negative MRD, would an autologous transplant followed by midostaurin maintenance be an option? Or would 1-year maintenance with midostaurin be a better option?Posted onMarch 10, 2022 5:14 pm
Silvia Jimenez, Mexico, what do the experts think about the use of circulating miRNAs to assess MRD, is it feasible?Posted onMarch 10, 2022 5:09 pm
2Posted onMarch 10, 2022 5:02 pm
Jorge Illarramendi Spain: We recently treat a patient with 3+7 and VO and he suffered sinusoidal obstruction syndrome. You will continue with VO in the next cycle. Thank youPosted onMarch 10, 2022 4:56 pm
Laurent Dewispelaere (Belgium): To Jan, did you compare your IGH/TCR MRD results to commercial NGS methods (f.e. Invivoscribe Lymphotrack)? Posted onMarch 10, 2022 4:44 pm
to Sylvie: How many cells do you analyse for Flow MRD?Posted onMarch 10, 2022 4:30 pm
****** Session 2 *********Posted onMarch 10, 2022 4:00 pm
ThanksPosted onMarch 10, 2022 3:59 pm
to Marielle: How do you treat Patients with MPAL who are Bcr-Abl positive? Posted onMarch 10, 2022 3:51 pm
Posted onMarch 10, 2022 3:42 pm
Can oxford nanopore sequencing replace the conventional cytogenetics? Dr SanjeevPosted onMarch 10, 2022 3:41 pm
I would like to ask the pannel two questions about maintenance treatment in ALL. First if the there is any data about the ideal TKI mantainance in BCR-ABL+ ALL (especially after AlloSCT) and secondly if there are is any maintenace treatment for T-ALL Posted onMarch 10, 2022 3:39 pm
Can we have ETP ALL without expression of CD34/CD117/TdT or any other stem cell marker?Posted onMarch 10, 2022 3:30 pm
Should all patients with T-ALL be consolidated with allogeneic stem cell transplant if eligible?Posted onMarch 10, 2022 3:26 pm
.Posted onMarch 10, 2022 3:26 pm
Q to Dr Wendy Stock: Does ETP diagnosis need both stem cell and myeloid markers? As per the IPT definition, isn't it stem and/or myeloid with other defining feature like cCD3 but CD5 dim/absent, CD8-, CD1a- Thanks Dr Sanjeev Gupta (India)Posted onMarch 10, 2022 3:12 pm
H. Dombret (Paris): Given its T-cell suppressive effect, is ruxolitinib contra-indicated in combination with T-cell engaging drugs?Posted onMarch 10, 2022 3:04 pm
D Posted onMarch 10, 2022 3:00 pm
Posted onMarch 10, 2022 2:57 pm
BPosted onMarch 10, 2022 2:57 pm
How often should we administer CNS prophylaxis via IT in MPAL with t(9;22) before allo-transplant? Thank you, Joana - PortugalPosted onMarch 10, 2022 2:53 pm
D Dr Sanjeev Gupta IndiaPosted onMarch 10, 2022 2:53 pm
ABL sequencing will allow knowing that optimal ITKPosted onMarch 10, 2022 2:52 pm
DPosted onMarch 10, 2022 2:52 pm
a Posted onMarch 10, 2022 2:52 pm
Posted onMarch 10, 2022 2:52 pm
Hello! My livestream is freezing. Is there a chance to fix that? Posted onMarch 10, 2022 2:38 pm
I would like to ask Elli Papaemmanouil: The combination of WT1 mutation with NPM1 mutation in AML has been proposed as an adverse risk combination by some recent opinions. Have you reached the same conclusion in your research? Congratulations for your great work and talk (Michael Diamantidis, Greece)Posted onMarch 10, 2022 2:35 pm
Do you think it is important to analyze the allelic affectation of TP53 for differential prognosis? If it is mono or biallelic? Thank you. Neus Ruiz, SpainPosted onMarch 10, 2022 2:33 pm
Question for Dr.Papaemmanuil: Allelic ratio of FLT3-ITD (low/high) most probably will be removed from the new ELN classification, but what about the the insertion site? There are data that patients with insertion limited in the juxtamembrane region do benefit from the addition of FLT3 inhibitors, whereas TKD1sole insertion and JMD/TKD1 insertion revealed as an unfavorable prognostic factor for OS and CIR in the RATIFY trial. Could insertion site further distinguish FLT3 patients and change treatment strategy? (e.g. transplantation in CR1 or not?) (Ioanna - Greece)Posted onMarch 10, 2022 2:33 pm
Posted onMarch 10, 2022 2:33 pm
Great talk. Would you please elaborate on the pros/cons of long read Nanopore seq. for karyotyping as opposed to SNParray? Thank you! Elsa BernardPosted onMarch 10, 2022 2:31 pm
To Prof. Bullinger: why did you not decide to do an allogenous Transplant to this patient with his high risk MDS befor he developes an AML? (Joanna Germany)Posted onMarch 10, 2022 2:27 pm
Posted onMarch 10, 2022 2:21 pm
Excellent work! sAML1and sAML2 subgroups being defined by the number of sAML-like mutations only (not the genes), this sub-discrimination doesn't not allow capturing the relative impact of each sAML-like gene taken individually. How these genes were distributed among the two groups?Posted onMarch 10, 2022 2:13 pm
Laurent Dewispealere (Belgium): Did you analyze the impact of single BZIP CEBPA mutation compared to biallelic CEBPA mutation in prognosis stratification? Posted onMarch 10, 2022 2:12 pm
***** Session 1 ********Posted onMarch 10, 2022 1:53 pm
With sequencing today many genetic alterations with specific white drugs are known. However, many do not achieve long survival. Do I have to increase medications?Posted onMarch 10, 2022 1:52 pm
Do you believe that PCR for FLT3-ITD detection will still be around even in the advent of WGS? (Ioanna - Greece)Posted onMarch 10, 2022 1:47 pm
not heardPosted onMarch 10, 2022 1:47 pm
Posted onMarch 10, 2022 1:46 pm
Xiao-Hua Luo(China): Most of AML patients have more mutations than gene fusions considering the age of this disease. Is it possible to weight the mutations and gene fusions for the prognosis and treatment program in your method?Posted onMarch 10, 2022 1:46 pm
Xiao-Hua Luo(China): Most of AML patients have more mutations than gene fusions considering the age of this disease. Is it possible to weight the mutations and gene fusions for the prognosis and treatment program in your method?Posted onMarch 10, 2022 1:46 pm
Thank you for this great talk! Were there any cases, to your knowledge, when WGS/NGS failed to detect mutations, and classical cytogenetics did? Could they be considered complementary methods? Dr. Zelic, CroatiaPosted onMarch 10, 2022 1:46 pm
Laurent Dewispelaere (Belgium). Does your cost analysis include personnel cost (both technician and analyst/geneticists)? Considering how labor intensive cytogenetics is compared to WGS, the latter could already be a valid alternative for cancer centers.Posted onMarch 10, 2022 1:46 pm
Thank you Dr Spencer, very interesting! Have you add any findings that were ambiguous for the origin of the mutation (somatic or germline) ? And cases where you would have benefited from adding a germline control ? Alexandre Rouette, CHU Sainte-Justine, Montreal, CanadaPosted onMarch 10, 2022 1:44 pm
Antonio Galleu, Italy: can you elaborate on the same OS observed for intermediate group and good risk group? Posted onMarch 10, 2022 1:41 pm
How soon do you consider that this methodology can be largely adapted, mainly outside academic centers and the US? And will the data alter finally the ELN risk classification based on co-mutations? (Ioanna - Greece)Posted onMarch 10, 2022 1:29 pm
How soon do you consider that this methodology can be largely adapted, mainly outside academic centers and the US? And will the data alter finally the ELN risk classification based on co-mutations? (Ioanna - Greece)Posted onMarch 10, 2022 1:29 pm
Posted onMarch 10, 2022 1:20 pm
Posted onMarch 10, 2022 1:20 pm
keynote Posted onMarch 10, 2022 1:16 pm
Posted onMarch 10, 2022 9:58 am
Testing 123Posted onMarch 10, 2022 8:09 am
testingPosted onMarch 9, 2022 10:13 pm